Cardiovascular and metabolic diseases including obesity remain important areas of unmet medical need, and we plan to continue applying our global capabilities to advance a pipeline of investigational treatments that have the potential to fill critical gaps in patient care, including continued development of our oral GIPR antagonist candidate and other earlier obesity programs, said Chris Boshoff, MD, PhD, Chief Scientific Officer and President, Research and Development at Pfizer
M., Quadros, E
Zhang Z, Zhang F, Guo X, An P, Tao Y, Wang F
In Johnson DS, Li JJ (eds.)
Ill give it one more month, provide another update
Being a part of the stage of drug development where a molecule gets tested in people for the first time struck me as something I wanted to be a part of